The pharmaceutical company Sinovac seeks to expand and strengthen the productive capacity of vaccines in Brazilian territory to the Fighting of sanitary crises. The initiative emerged after the emergency caused by the COVID-19 pandemic. At the time, the company came to provide about 100 million coronavac doses to the country in the critical months of the disease.
In Brazil, visiting the CNN the company’s vice president for Latin America, Weining Meng, showed that the largest production of vaccines in the country It means having more sanitary security.
“During the pandemic, we realize that the vaccine industry is not just a normal industry. It also means Health safety. This means that the local vaccine industry is crucial for the next pandemic. From then on, we see that all countries have this desire, and we also want to make the location of our product as something regional. Thus, we are very confident and optimistic that production becomes localized, ”said Meng in an interview with CNN .
The biggest focus in Brazil arrives after Sinovac’s successful performances in other regions, such as Turkey and Colombia, where I reduced dependence on imports expanding the country’s productive capacity. According to the company’s representative, with the investment, “we can do more research and studies to finally develop a good product and bring more benefits to the local population.”
“Latin America is a strategic priority for Sinovac. Our experience during the pandemic has reinforced the need for continuous investments to ensure that countries in the region have fast and safe access to vaccines,” Meng explained.
The vice president also explained more about the vaccine production expansion plan.
“During the pandemic we had the ability to build a very logical production capacity. We are willing to collaborate with our partner here [Butantan]. We can bring our other partners to quickly build production facilities, we have experience to produce large -scale, working together with a local partner, ”he said.
“With this, then, we can build and finish quickly and also make technical transfer with agility. Usually we talk about the technological transfer of the vaccine normally in 10 years, but we are very confident to shorten this period. For example, in Turkey, we conclude the entire production structure in 14 months. We are very confident in this. By shortening the period of construction and the technical period, we can estimate about five, six or seven years and actually make the vaccine and actually make the vaccine be produced. Locally here. ”
SINOVAC has already established partnerships for technology transfer to Brazil and continues to negotiate new collaborations in Brazil, including its participation in the Partnership Process for Productive Development (PDP) with the Paraná Institute of Technology (TECPAR), a Brazilian Public Institute.
“This is not just a project. Even collaboration with Tecpar, working together. After that, we can bring more vaccines, more production, to expand the scope. We can collaborate with our partners to do research local studies with animals… These also need more investments,” he said.
“I have a strong awareness that Brazil is a large country, large population, already has very good conditions for pharmaceutical industries. We want to work together with public and private institutes. We are also willing to work together with Anvisa. Finally, make a good preparation for the next pandemic,” concluded Meng.
*With collaboration by Nathalie Ayres, from CNN.
I am an advocate of the vaccine, says chairman of the Health Commission in the Chamber
This content was originally published in producing vaccines is to have more health safety, says Sinovac VP on CNN Brazil.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
